**Name of Journal: *World Journal of Hepatology***

**ESPS Manuscript NO: 24149**

**Manuscript Type: Topic Highlight**

**2016 Liver Transplantation: Global view**

**Incidence, risk factors and outcomes of *de novo* malignancies post liver transplantation**

Mukthinuthalapati PK *et al.* Cancers occurring after LT

**Pavan Kedar Mukthinuthalapati, Raghavender Gotur, Marwan Ghabril**

**Pavan Kedar Mukthinuthalapati, Raghavender Gotur, Marwan Ghabril,** Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, IN 46202, United States

**Author contributions:** Mukthinuthalapati PK interpretation of literature, drafting and final approval of the article; Gotur R interpretation of literature, drafting and final approval of the article; Ghabril M interpretation of literature, drafting and final approval of the article.

**Conflict-of-interest** **statement:** All the authors have no conflicts to report.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Correspondence to: Marwan Ghabril, MD, Associate Professor** of Medicine,Division of Gastroenterology and Hepatology, Indiana University School of Medicine, 702 Rotary Circle 225, Indianapolis, IN 46202, United States. mghabril@iu.edu

**Telephone**: +1-317-2781630

**Fax**: +1-317-2786870

**Received:** January 9, 2016

**Peer-review started:** January 10, 2016

**First decision:** February 22, 2016

**Revised:** March 8, 2016

**Accepted:** April 5, 2016

**Article in press:**

**Published online:**

**Abstract**

Liver transplantation (LT) is associated with a 2 to 7 fold higher, age and gender adjusted, risk of *de novo* malignancy. The overall incidence of *de novo* malignancy post LT ranges from 2.2% to 26%, and 5 and 10 year incidence rates are estimated at 10% to 14.6% and 20% to 32%, respectively. The main risk factors for *de novo* malignancy include immunosuppression with impaired immunosurveillance, and a number of patient factors which include; age, latent oncogenic viral infections, tobacco and alcohol use history, and underlying liver disease. The most common cancers after LT are non-melanoma skin cancers, accounting for approximately 37% of *de novo* malignancies, with a noted increase in the ratio of squamous to basal cell cancers. While these types of skin cancer do not impact patient survival, post-transplant lymphoproliferative disorders and solid organ cancer, accounting for 25% and 48% of malignancies, are associated with increased mortality. Patients developing these types of cancer are diagnosed at more advanced stages, and their cancers behave more aggressively compared with the general population. Patients undergoing LT for primary sclerosing cholangitis (particularly with inflammatory bowel disease) and alcoholic liver disease have high rates of malignancies compared with patients undergoing LT for other indications. These populations are at particular risk for gastrointestinal and aerodigestive cancers respectively. Counseling smoking cessation, skin protection from sun exposure and routine clinical follow-up are the current approach in practice. There are no standardized surveillance protocol, but available data suggests that regimented surveillance strategies are needed and capable of yielding cancer diagnosis at earlier stages with better resulting survival. Evidence-based strategies are needed to guide optimal surveillance and safe minimization of immunosuppression.

**Key words:** Liver transplant; Malignancy; Immunosuppression; Risk; Outcomes

**© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** The risk of new cancers is significantly increased after liver transplantation, and is driven by patient factors, oncogenic viruses and lifelong immunosuppression.De novo malignancy is a major risk factor for mortality after liver transplantation, equaling the risk of cardiovascular disease or infectious diseases. The risk of *de novo* malignancies may be reduced by attention to patient risk factors and minimization of immunosuppression when possible. Ultimately rigorous surveillance is needed to allow for early diagnosis and attenuation of mortality risk.

Mukthinuthalapati PK, Gotur R, Ghabril M. Incidence, risk factors and outcomes of de novo malignancies post liver transplantation. *World J Hepatol* 2016; In press

**INTRODUCTION**

Liver transplantation (LT) is the definitive therapy for decompensated end-stage liver disease regardless of etiology. During the past 2 decades, the outcomes of LT have steadily improved as a result of more widespread expertise, better surgical techniques and more effective and better tolerated immunosuppressive agents. The growing number of LT recipients and improving survival rates place particular importance on the factors that jeopardize long term survival. Inherent to this population is the need for lifelong immunosuppression, which is associated with some broad categories of risk for morbidity and mortality. These include infection, cardiovascular risks, renal injury and cancer. When studied in patients surviving the early post LT period, *de novo* malignancy emerges as the leading category of immunosuppression associated long term mortality risk, accounting for approximately 21% to 25% of deaths[[1](#_ENREF_1),[2](#_ENREF_2)]. This review summarizes current knowledge of *de novo* malignancy post LT including; epidemiology, pathogenesis, disease burden, clinical implications, preventive and surveillance considerations, while emphasizing risk factors and outcomes.

**INCIDENCE**

Multiple studies report widely varying incidence rates of *de novo* malignancy post LT, along with considerable variations in associated risks, cancer types and outcomes. The incidence of *de novo* malignancies in relatively large cohorts (subjectively defined as more than 150 patients) is summarized in Table 1, the last row of which contains the means of the respective variables. These include single center experiences[[3-7](#_ENREF_3)], registry based studies[[8-11](#_ENREF_8)], and the majority are retrospective with few exceptions[[12](#_ENREF_12)]. Variability in *de novo* malignancy incidence rates reflect actual differences (based on differing cohort characteristics and risks) and artificial differences (based on differing methodologies and study design). The factors impacting actual differences in cancers types and their incidence may include age, gender, racial and geographical considerations, as well as the predominant underlying liver diseases and their associated comorbidities. Whereas artificial heterogeneity may be less apparent, yet could arise from variability in the; (1) definitions of *de novo* malignancy, e.g. not all include non-melanoma skin cancers; (2) designated time threshold for of exclusion of cancers that are likely pre-existing before LT; (3) method of identification of malignancies, *e.g.,* in-center chart review versus utilization of cancer registries; (4) surveillance protocols and frequency of clinical follow up at study centers (critical for in-center reporting of cancer cases); (5) duration of follow up post LT since cancer incidence increases with time[[8](#_ENREF_8),[13](#_ENREF_13)]; and (6) in the case of standardized incidence ratio (SIR) calculations, the control population used and type of cancers captured by the respective registries. In this review, we have described incidence rates of cancers and as well as the SIR where possible, as it allows age and gender adjusted risk analysis. SIR is calculated as the ratio of observed incidence in a cohort to the expected incidence in the population (hence has no unit).

Cancer registry data used to calculate expected age and gender adjusted incidence rates for SIR estimation doesn’t capture non-melanoma skin cancers (NMSCs). Therefore SIR analyses succinctly reflect the risk of more life-threatening types of cancer. Interestingly, purely registry based analyses yield higher SIR values for *de novo* malignancy post LT, ranging from 2.2 to 4.9 ([10](#_ENREF_10), [14-16](#_ENREF_14)), than 1.4 to 3.1 ([2](#_ENREF_2), [9](#_ENREF_9), [11](#_ENREF_11), [17](#_ENREF_17), [18](#_ENREF_18)) of single and multi-center studies. The reasons for this are unclear but could reflect differing approaches to immunosuppression given the reporting bias for higher transplant volume centers.

**RISK FACTORS FOR *DE NOVO* MALIGNANCY**

The risk factors for the development of *de novo* malignancy after liver transplantation are not fully understood, but it is likely that patient, transplant and environmental factors interact to shape that risk.

***Immunosuppression related risk***

Over the past few decades, a better understanding of the role of the immune system in preventing malignancy in immunocompetent individuals helped establish the concept of immunosurveillance[[19](#_ENREF_19)]. Transplant recipients receive lifelong immunosuppression with chronic impairment of immunosurveillance, which promotes proliferation and survival of malignant cellular clones. Though immunosuppressive drug dose intensity likely contributes to cancer risk, the evidence for this is indirect. Comparative studies indicate a lower SIR for *de novo* malignancies in LT (2.2) recipients compared with heart (2.5) or lung (3.6) recipients who typically require higher intensity of immunosuppression[[16](#_ENREF_16),[20](#_ENREF_20)]. A higher rate of hepatocellular carcinoma recurrence has been described with higher trough levels of the calcineurin inhibitors (CNI), tacrolimus and cyclosporine, particularly in the early post LT period[[21](#_ENREF_21),[22](#_ENREF_22)]. Calcineurin inhibitors inhibit T-lymphocyte cell mediated immunity, and may also increase the risk of malignancy by increasing synthesis of growth factors, *e.g.,* transforming growth factor-β, interleukin-6 and vascular endothelial growth factor in tumor cells, and impair DNA repair, thereby enhancing tumor growth, metastasis and angiogenesis[[23](#_ENREF_23)]. The duration of immunosuppression also likely increases risk of malignancy, with increased incidence reported in recipients who were immunosuppressed before LT[[9](#_ENREF_9)].

The choice of immunosuppressive drug is a potentially modifiable cancer risk factor. Cyclosporine initially, and tacrolimus subsequently, have been and remain the mainstay of long term immunosuppression in liver transplantation over the last few decades. Even though some studies have shown higher carcinogenic risk with tacrolimus[[7](#_ENREF_7),[24](#_ENREF_24)], and others with cyclosporine based protocols[[2](#_ENREF_2),[25-27](#_ENREF_25)], there is no accepted cancer risk advantage for either agent[[3](#_ENREF_3),[28](#_ENREF_28)]. A more practical concern in choice of immunosuppressant relates to the class of mammalian target of rapamycin (mTOR) inhibitors, sirolimus and everolimus, though these agents are used mainly in renal sparing regimens. The putative anti-proliferative properties of mTOR inhibition include inhibition of cellular growth, proliferation, metabolism and angiogenesis[[29](#_ENREF_29)]. Though there is no prospective randomized controlled study data currently, a number of retrospective studies have described lower rates of hepatocellular carcinoma (HCC) recurrence[[30](#_ENREF_30),[31](#_ENREF_31)], and *de novo* malignancies[[32](#_ENREF_32),[33](#_ENREF_33)] with mTOR inhibitors post LT and renal transplantation[[34](#_ENREF_34)]. A meta-analysis of retrospective studies has shown that mTOR inhibitor, sirolimus, is of value in preventing recurrence and increasing survival in those transplanted for HCC[[35](#_ENREF_34)].

The post LT cancer risk related to anti-metabolites has been described for azathioprine in one study, with an odds ratio (OR = 3.8, 95%CI: 1.7 - 8.6, *P* = 0.004)[[36](#_ENREF_34)]. Whereas mycophenolate mofetil has been shown to have anti-tumor properties in animal studies[[37](#_ENREF_34)], and was associated with a trend towards lower risk of non-skin *de novo* malignancies post renal transplant in a large United States, and European/Canadian registry based study[[38](#_ENREF_34)]. In a recent study of solid organ transplant, mycophenolate mofetil use was associated with lower risk of proximal colon cancer[[39](#_ENREF_34)].

Immunosuppression induction with anti-lymphocyte antibodies or anti-thymocyte globulin was associated with increased of skin cancer in one study[[9](#_ENREF_34)], however that risk was not seen in larger series using anti-thymocyte globulin induction[[2,28](#_ENREF_34)]. Rejection episodes also did not alter the risk of malignancy in LT recipients[[5,6,12,40](#_ENREF_34)]. These data suggest that higher levels of immunosuppression in the short term do not increase the long term risk of cancer.

Immunosuppression also increases the cancer risk related to latent oncogenic virus infections (Table 2)[[41](#_ENREF_34)]. Oncogenic virus associated tumors may be more immunogenic than those related to other factors, and may regress once immunosuppression is stopped or minimized[[42](#_ENREF_34)]. This provides the rationale for a decrease in immunosuppression as the first line intervention for some virus related cancers, such post-transplant lymphoproliferative disorder (PTLD), particularly when associated with Epstein-Barr virus (EBV) viremia[[43](#_ENREF_34)].

***Recipient related factors***

The association of specific patient factors with cancer risk are organized and elaborated on below.

**Age:** Advanced age is a well described risk factor for *de novo* malignancy[[2,7,8,12,44,45](#_ENREF_34)], although this is not a universal finding[[25,28](#_ENREF_34)]. This suggests that other factors may supersede age in cancer risk, though some caveats are notable with the extremes of age. For example the SIR for early PTLD was high (18.1) in pediatric LT recipients in one study[[9](#_ENREF_34)], with a similar observation in another study[[10](#_ENREF_34)]. In another study, LT recipients older than 60 had > 2 fold higher 5-year incidence of new cancers (> 40%) compared to younger LT recipients (< 20%), largely due to non-skin cancers, with significantly higher cancer related mortality[[46](#_ENREF_34)].

**Gender and race:** There is conflicting data on the relative risk of *de novo* malignancy according to gender, with slightly higher SIR of cancers in females in one registry study[[14](#_ENREF_34)], and in males in another[[45](#_ENREF_34)], limiting any meaningful conclusion. Although skin cancer risk would be expected to differ according to race, there is limited data of cancer risk in relation to race. Non-Caucasian race was associated with a higher hazard ratio (HR 2.5, 95%CI: 1.3-4.3) for non-skin cancers in one study, but the small size of that subgroup was limiting[[2](#_ENREF_34)].

**Indication for liver transplantation:** Patients who receive LT for certain indications are more prone for some malignancies. Patients with primary sclerosing cholangitis (PSC) in a U.S. multicenter prospective observational study had the highest cumulative incidence of non-skin cancer of 5.5%, DOI: 10.4%, and 21.9% at 1, 5, and 10 years, respectively[[12](#_ENREF_34)]. Patients with PSC and inflammatory bowel disease (IBD) and an intact colon at the time of LT were at increased risk of GI (colon) malignancy (HR = 2.34, 95%CI: 1.02−5.38)[[12](#_ENREF_34)], which may not be surprising given the association of PSC and IBD with colon cancer risk. However, patients with PSC also exhibited an increased risk for PTLD, skin malignancies and solid organ malignancies[[12](#_ENREF_34)]. A high cancer risk for LT recipients with PSC was also observed in an Italian study, though cancer types were not specified[[47](#_ENREF_34)]. The reasons for generalized cancer risk are unclear, but may reflect immunosuppression before LT, and possibly vitamin D deficiency which may promote malignancy[[48](#_ENREF_34)].

**Alcohol use history and smoking:** Many studies have revealed the carcinogenic properties of alcohol and alcohol in normal immunocompetent individuals[[49,50](#_ENREF_34)]. Alcoholic liver disease (ALD) is associated with increased cancer risk post LT[[7](#_ENREF_7),[12](#_ENREF_12),[36](#_ENREF_36),[45](#_ENREF_45),[51-54](#_ENREF_51)]. Synergy between the carcinogenic effects of alcohol and smoking is well described[[55,56](#_ENREF_34)]. Smokers were more likely to have alcoholic liver disease than non-smokers (35% *vs* 13%, P= 0.008) in one study[[56](#_ENREF_34)], and patients transplanted for ALD were more likely to be smokers (82% *vs* 45%, P = 0.001) and smoked more number of cigarettes per day (27 ± 15 *vs* 16 ± 11, P = 0.001) in another[[54](#_ENREF_34)]. A United Kingdom registry study reported a higher SIR (3.16) of *de novo* malignancy for ALD compared to all other LT indications (1.99)[[45](#_ENREF_34)]. In the immunocompetent population, there is evidence that the increased risk of cancer due to alcohol abuse could be reversed by abstinence[57]. However, this effect may be delayed by a more than a decade[[58](#_ENREF_34)], with cancer risk carried through post LT.

**History of cancer prior to LT:** A history of cancer prior to LT was not associated with its recurrence after LT[[8,25](#_ENREF_34)]. However, LT for HCC has been associated with an increased risk of *de novo* malignancy[[7,44](#_ENREF_34)]. An increased incidence of non-skin cancers in patients with a history of non-liver cancer prior to LT (30.8% *vs* 8.3%, *P* = 0.001) has also been described, where it was additionally an independent predictor of non-skin *de novo* malignancies (HR = 2.5, 95%CI: 1.3-4.9, *P* = 0.005)[[2](#_ENREF_2)]. This association is supported by data from renal transplantation studies[[34](#_ENREF_34),[59](#_ENREF_59),[60](#_ENREF_60)]. Therefore, a prior history of cancer may reflect a patient’s composite (genetic and epigenetic) risk of malignancy.

**SITE SPECIFIC *DE NOVO* MALIGNANCIES**

The risk of *de novo* malignancy is variable across a range of tumor types, as reported by cancer registry studies. These cancers are commonly grouped according to three broad categories including; skin cancers, PTLD and solid organ cancers. The risks of specific tumors post LT are summarized in Table 3.

***Skin cancers***

Skin malignancy, typically non-melanoma skin cancer (NMSC), is the most common malignancy after LT[[2](#_ENREF_2),[7](#_ENREF_7),[9](#_ENREF_9),[12](#_ENREF_12),[40](#_ENREF_40),[61](#_ENREF_61)]. These include squamous cell cancer (SCC), basal cell cancer (BCC) and KS. Ultraviolet radiation is an important risk factor in the pathogenesis of skin malignancies, and exerts a field cancerization mutagenic effect in exposed areas of the skin[[62-65](#_ENREF_62)]. In a prospective study of LT recipients with comprehensive dermatology follow-up, only total pre transplant sun burden and skin characteristics were found to be the risk factors for NMSC[[66](#_ENREF_66)]. The relative risk of cutaneous malignancies in this cohort was found to be 20 fold higher than the general population. Conversely studies from Iran, Korea and China described no to very low incidence rates of skin cancer, likely due to the prevalent skin types[[67-69](#_ENREF_66)]. In organ transplant recipients, SCC is more common than BCC, in contrast to the general population[[44,70](#_ENREF_66)] . Additionally, while SCC and BCC are easily surveyed and resected, SCC can behave more aggressively in LT recipients[[70,71](#_ENREF_66)]. In general though, LT recipients with SCC and BCC have similar survival to patients not developing *de novo* malignancies post LT[[2,40](#_ENREF_66)].

Immunosuppression with CNIs and azathioprine is a significant risk factor for NMSC[[72-76](#_ENREF_66)], but is likely the degree of immunosuppression that represents the main risk rather than the choice of agent[[62,77,78](#_ENREF_66)]. However, there is mounting evidence that mTOR inhibitors have protective effect against NMSC due to their aforementioned anti-proliferative properties[[72,77](#_ENREF_66)], especially in renal transplant recipients. In a randomized trial, converting renal transplant recipients with NMSC from CNI to sirolimus based immunosuppression was associated with a reduced risk of subsequent NMSC (relative risk 0.56, 95%CI 0.32 -0.98) and longer recurrence free interval (15 mo *vs* 7 mo, *P* = 0.02)[[79](#_ENREF_66)]. However, similar evidence in LT recipients is currently lacking.

Kaposi’s sarcoma is related to HHV-8 virus and occurs only in immunocompromised individuals. The incidence of KS after LT reflects the prevalence of HHV8 (also known as Kaposi's sarcoma-associated herpes virus), with high rates reported in the Mediterranean region[[80,81](#_ENREF_66)]. Not surprisingly the highest rates and SIR (commonly > 100) for KS post LT are reported in Italian transplant series[[11,17,47](#_ENREF_66)].

***Post-transplant lymphoproliferative disorders***

The term PTLD encompasses a broad spectrum of lymphoproliferative disorders observed in the immunocompromised solid organ transplant recipients. It is the second most common malignancy in LT recipients, and is notable in its wide age distribution, extending to the very young[[14](#_ENREF_66)]. The rate of PTLD is lower in the liver compared to other solid organ recipients[[82](#_ENREF_66)], likely due to lower immunosuppression levels needed to prevent liver allograft rejection, and possibly a smaller number of donor lymphocytes in the graft[[83](#_ENREF_66)]. The other factor driving PTLD risk is EBV infection, with associated PTLD generally occurring earlier, in the first 12 to 18 mo, after LT and involving younger patients[[82,84](#_ENREF_66)]. Infection with EBV and immunosuppression appear to play crucial roles in the pathogenesis of PTLD. EBV mismatch between donor and recipient of LT increases the risk of PTLD by 70 fold[[85,86](#_ENREF_66)]. Primary infection with EBV after LT also increases the risk significantly[[87](#_ENREF_66)]. Primary EBV or latent (of virus within B cells) infection can stimulate B cell proliferation and transformation[[88](#_ENREF_66)]. EBV associated PTLD occurs three times more frequently in pediatric patients[[87,89](#_ENREF_66)]. This is likely a reflection of the EBV negative status of pediatric recipient, whereas EBV infects 90% of the adults worldwide[[90](#_ENREF_66)].

Another important phenotype of PTLD develops later post LT in the absence of EBV infection involves older recipients and carries a worse prognosis[[82](#_ENREF_66)]. The pathogenesis of EBV negative PTLD is uncertain[[91](#_ENREF_66)], but some risk factors were described in a study of 480 adult LT recipient PTLD in France, where 16 developed PTLD[[92](#_ENREF_66)]. These were age above 50, LT for HCV or alcoholic cirrhosis, and the use of anti-lymphocyte antibodies such as muromonab, the latter reported by others[[82,87](#_ENREF_66)]. The use of anti-thymocyte globulins in LT for HCV cirrhosis augmented PTLD risk in another study (27% for HCV *vs* 6.4% for non-HCV cases, *P* = 0.08)[[93](#_ENREF_66)]. When compared to lymphomas in the immunocompetent population, PTLD are more likely to exhibit extra-nodal involvement, high-grade and poor outcomes[[94](#_ENREF_66)]. Factors which confer a poor prognosis with PTLD are; high grade or stage at diagnosis[[43](#_ENREF_66)], T cell disease[[95](#_ENREF_66)], central nervous system and bone marrow involvement[[96,97](#_ENREF_66)], poor performance status[[98](#_ENREF_66)], higher number of extra-nodal sites[[98](#_ENREF_66)], and EBV negative disease[[43,85,99](#_ENREF_66)].

***Solid organ cancers***

Like PTLD, this category of *de novo* malignancy carries significant risk of mortality post LT, but is a term loosely used to group a wide range of tumor types and organ involved. Some characteristics of risk are evident in relation to subgroups of solid organ cancers, including aerodigestive, gastrointestinal cancers, and genitourinary and gynecologic systems.

***Aerodigestive cancers***

Aerodigestive cancers are associated with smoking and alcohol use, and arise from the tissues of the aerodigestive tract, which include the respiratory tract and the upper part of the digestive tract (including the lips, mouth, tongue, nose, throat, vocal cords, and part of the esophagus and windpipe. These are largely reported as head and neck cancers and lung cancer post LT.

A meta-analysis of studies examining head and neck cancer after LT found an overall SIR of 3.8 (95%CI: 2.7-4.9)[[100](#_ENREF_66)]. They develop at mean post LT intervals that range from 34 to 61 mo[[3-5,92,101](#_ENREF_66)]. Liver transplant recipients with a history of tobacco use and ALD are at high risk for developing head and neck cancers[[7,12,102](#_ENREF_66)], and in some studies only developed in patients with a history of ALD[[6,103](#_ENREF_66)].

In a large study encompassing all solid organ transplants in the United States, the SIR for lung cancer after LT was found to be 1.95(95%CI: 1.74-2.19)[[14](#_ENREF_66)]. Lung cancer develops at mean post LT intervals ranging from 42 to 50 mo[[3,5,28,61,101](#_ENREF_66)]. The main risk factors for lung cancer, similar to the general population, in LT recipients was smoking[[2,7,12,54](#_ENREF_66)]. Those transplanted for ALD also had increased risk of lung cancer compared to those transplanted for other causes (4.3% *vs* 0.7%, *P* < 0.001), though tobacco use which prevalent in this population may confound these observations[[7,12,54](#_ENREF_66)]. Post LT lung cancer are commonly diagnosed in advanced stages[[3,5,54](#_ENREF_66)], suggesting diligent surveillance programs in the high risk population (smokers and those transplanted for ALD). It remains unclear how long tobacco and alcohol related cancer risk persist following cessation.

***Gastrointestinal cancers***

The most common gastrointestinal cancer seen in solid organ transplant recipients is colon cancer[[14](#_ENREF_66)]. The SIR for colon cancer in LT recipients ranges from 1.4 to as high 27.3 in subsets of high risk patients with PSC[16,17,45]. Patients receiving LT for PSC are at particularly high risk for colon cancer, due to the association with IBD[12,45,104,106]. In the study by Watt *et al*[12] PSC alone (HR = 1.9, *P* = 0.12) was not a risk factor for gastrointestinal malignancy, whereas patients with PSC, IBD and intact colons had a significant cancer risk (HR = 3.51, 95%CI: 1.48–8.36, *P* = 0.005). Colon cancer was more common in LT recipients with ulcerative colitis (SIR 27.3 *vs* 3.5), than those without it, particularly in patients older than 40 (SIR 4.8 *vs* 1 in younger patients)[45]. Longer duration of IBD and more extensive colonic involvement increase the risk for colorectal cancer in LT recipients with PSC[104-106]. Colorectal cancer develops at a younger age in LT recipients compared with the general population, and has a worse prognosis[107-108]. A relatively high incidence of colon and stomach cancer have been reported in a Korean study[67], with otherwise relatively low (2.2-2.3%) *de novo* malignancy incidence rates reported in East Asian studies[67,69].

***Genitourinary and gynecologic cancers***

Registry studies indicate an increased SIR of some (cervical, vulvar, bladder and kidney) but not all genitourinary or female (breast, prostate, uterine, ovarian) cancers following solid organ transplant[10,14-17,45], and in the largest of these slightly lower SIR for breast and prostate cancer in transplant recipients[14]. Cervical cancer risk was significantly elevated in one series (SIR 30.7)[17], and other Human Papilloma virus related cancers (vulvar, vaginal, anal, penile) all appear have higher SIR (range 2.4 - 7.6) relative to the general population[14]. Bladder cancer risk is increased in a number of studies, with a range of SIR value from 1.5 to 2.4[14-16], and were noted to develop late (10 years) post LT in one cohort[47].

**SURVIVAL AFTER DE NOVO NON-SKIN CANCERS**

In a comparison of patients from a solid organ transplant cancer registry with a general population from the Surveillance, Epidemiology, and End Results database, transplant patients were more likely to be diagnosed with American Joint Commission on Cancer stage > 2 cancers, and worse cancer-specific survival[109]. The relative risk of cancer-related mortality compared to the general population was 2.9 (95%CI: -1.59-5.11)[7]. In a large single center study *de novo* malignancy, excluding NMSC, was a leading category of mortality risk (14.2%), along with infections (15%), disease recurrence (13%) and cardiovascular (9%) complications[2]. Patient survival rates at 1.3 and 5 years *after* diagnosis of *de novo* malignancy were 55%, 36%, and 27% compared with 100%, 100% and 67% for patients with only NMSC , *P* = 0.001, respectively[2]. Similarly, *de novo* malignancy excluding NMSC was associated with an increased risk of mortality [HR =4.9 (95%CI: 1.67–14.2), *P* = 0.003] in another large series[40], and probability of death after diagnosis was 40% at 1 year, and 55% at 5 years, respectively[12].

There is considerable variability in reported survival after PTLD, with median survival as low as 2 mo (95%CI: 0.3-3.5 mo) in one study[36], likely as a result of heterogeneity in risk characteristics of PTLD[95]. Longer median survival intervals (27 mo to 35 mo) are noted in other LT series[12,14], with reported 1 and 5 year survival rates of 56% and 46%, respectively[82]. Pediatric LT recipients with PTLD appear to have better outcomes, with median survival of 8.2 years and reported 10 year survival rates of 59%[85,96], and no reported mortality in some series[94]. Advanced stage, Burkitt or Burkitt-like PTLD, and c-myc translocations indicated poor prognosis and short survival in pediatric PTLD[96].

The reported site-specific cancer survival rates for the aforementioned solid organ cancer categories are: oropharyngeal cancer1 and 5 year survival of 43% to 78% and 56% respectively, lung cancer 1 and 5 year survival of 41% to 43% and 16% respectively, gastrointestinal cancers 1 and 5 year survival of 67% to 80% and 52% respectively, and genitourinary cancers 1 and 5 year survival of 79%-100% and 71% respectively[3,12] .

**SURVEILLANCE**

The increased risk and mortality associated with *de novo* malignancies underlines the need for surveillance strategies to detect tumors at earlier stages, allow more effective treatments, and improve survival. However, there are no standardized surveillance protocols for LT recipients at present. Routine follow up visits alone were only capable of detecting 12% of the non-skin cancers in one series, and annual visit resulted in identifying half of all malignancies in another[8,9]. Poor compliance with surveillance protocols was also cited a limitation in study where active surveillance identified only 3 of 28 non-skin cancers[7]. These data further highlight the need for regimented surveillance strategies in this regard.

In a compelling study, the incidence and outcome of *de novo* malignancy were compared before and after institution of an intensified surveillance protocol which included: annual chest and abdominal computerized tomography (CT), urological, gynecological (pap smear and mammography) and dermatological examination, and colonoscopies every 5 years[18]. With a historical surveillance program consisting of annual chest radiographs and abdominal ultrasounds serving as the reference comparator, the detection rate for *de novo* malignancies increased from 4.9% to 13% with intensified surveillance (*P* = 0.001), fewer tumors were diagnosed at stage III or IV (46% *vs* 75%), and median survival following a diagnosis of non-skin cancer increased from 1.2 to 3.3 years (*P* = 0.001) [18].

At another center, a similarly multifaceted surveillance protocol that included: (1) urinalysis, chest radiographs and abdominal ultrasounds performed every 6 months in the first year post LT and annually thereafter; (2) mammography every two years; (3) colonoscopy every 7-10 years if no adenomas were detected; and (4) in patients with smoking history, an annual otolaryngological evaluation and low dose CT of the chest after 2006[110]. Patients that were diagnosed with *de novo* malignancy through active surveillance had better survival (all were alive after 25 months of follow up) compared with patients diagnosed with symptomatic disease or incidentally (median survival of 13.5 months) (*P* = 0.002)[110]. The use of annual low dose chest CT in LT recipients with more than 10 pack years of cumulative smoking history led to a diagnosis of early stage lung cancer in 12% of patients[111].

Additionally, special populations amongst LT recipient and the specialized surveillance strategies that are or may be warranted for them include those with: (1) underlying PSC and IBD, or IBD alone of more than 8-10 years duration with annual surveillance colonoscopy; (2) a history of Human Papilloma virus infection with annual pap smear in females, and annual genital and anal pap/scraping in both genders; and (3) patients from the Mediterranean region with testing of Human Herpes Virus-8 titers due to increased prevalence and association with risk of KS[112].

**PREVENTATIVE MEASURES**

Smoking is a major risk factor for cancer, especially nasopharyngeal cancers and lung cancer, as well cardiovascular disease related mortality[56], and smoking cessation should be counseled as early as possible. Regular application of broad spectrum sunscreen (SPF > 50, with high-UVA absorption) over sun-exposed areas in solid organ transplant recipients, in conjunction with counseling of excessive sun exposure avoidance, reduced the risk of actinic keratosis, invasive SCC and BCC from developing in a prospective case control study in solid organ transplant recipients[113]. Protective clothing has also been shown to protect against UV radiation[114].The minimization of immunosuppression without risking graft rejection is limited by the lack of accurate markers of over or under immunosuppression, but would likely to attenuate the risk of *de novo* malignancy in LT recipient. There is also insufficient evidence to guide the routine use of mTOR inhibitors in at risk patients, but those studies are ongoing[115-120].

**CONCLUSION**

Liver transplant recipients are at increased risk of cancer when compared to the general population, and the most commonly encountered cancers are NMSC, PTLD, and aerodigestive. They are due mainly due to the effects of immunosuppression and latent oncogenic viruses prevalent in the population. Important risk factors for development of *de novo* malignancy include age, degree of immunosuppression, history of smoking and alcohol abuse and transplantation for PSC and HCV. *De novo* malignancies, excluding NMSC, represent a major risk category for post LT mortality. There are no standardized surveillance protocols for *de novo* malignancy post LT, but available evidence supports adoption of some consistent surveillance strategies. Minimization of immunosuppression and attention and counseling related to other risk factors in LT recipients may reduce an individual's risk of developing cancers post LT, but more evidence is needed to optimize care.

**REFERENCES**

1 **Pruthi J**, Medkiff KA, Esrason KT, Donovan JA, Yoshida EM, Erb SR, Steinbrecher UP, Fong TL. Analysis of causes of death in liver transplant recipients who survived more than 3 years. *Liver Transpl* 2001; **7**: 811-815 [PMID: 11552217 DOI: 10.1053/jlts.2001.27084]

2 **Chatrath H,** Berman K, Vuppalanchi R, Slaven J, Kwo P, Tector AJ, Chalasani N, Ghabril M. De novo malignancy post-liver transplantation: a single center, population controlled study. *Clin Transplantat* 201; 27: 582-590 [PMID: 23808800 DOI: 10.1111/ctr.12171]

3 **Jain AB**, Yee LD, Nalesnik MA, Youk A, Marsh G, Reyes J, Zak M, Rakela J, Irish W, Fung JJ. Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data. *Transplantation* 1998; **66**: 1193-1200 [PMID: 9825817 DOI: 10.1097/00007890-199811150-00014]

4 **Saigal S**, Norris S, Muiesan P, Rela M, Heaton N, O'Grady J. Evidence of differential risk for posttransplantation malignancy based on pretransplantation cause in patients undergoing liver transplantation. *Liver Transpl* 2002; **8**: 482-487 [PMID: 12004349 DOI: 10.1053/jlts.2002.32977]

5 **Sanchez EQ**, Marubashi S, Jung G, Levy MF, Goldstein RM, Molmenti EP, Fasola CG, Gonwa TA, Jennings LW, Brooks BK, Klintmalm GB. De novo tumors after liver transplantation: a single-institution experience. *Liver Transpl* 2002; **8**: 285-291 [PMID: 11910575 DOI: 10.1053/jlts.2002.29350]

6 **Schmilovitz-Weiss H**, Mor E, Sulkes J, Bar-Nathan N, Shaharabani E, Melzer E, Tur-Kaspa R, Ben-Ari Z. De novo tumors after liver transplantation: a single-center experience. *Transplant Proc* 2003; **35**: 665-666 [PMID: 12644086 DOI: 10.1016/S0041-1345(03)00089-7]

7 **Herrero JI**, Lorenzo M, Quiroga J, Sangro B, Pardo F, Rotellar F, Alvarez-Cienfuegos J, Prieto J. De Novo neoplasia after liver transplantation: an analysis of risk factors and influence on survival. *Liver Transpl* 2005; **11**: 89-97 [PMID: 15690541 DOI: 10.1002/lt.20319]

8 **Haagsma EB**, Hagens VE, Schaapveld M, van den Berg AP, de Vries EG, Klompmaker IJ, Slooff MJ, Jansen PL. Increased cancer risk after liver transplantation: a population-based study. *J Hepatol* 2001; **34**: 84-91 [PMID: 11211912 DOI: 10.1016/S0168-8278(00)00077-5]

9 **Aberg F**, Pukkala E, Höckerstedt K, Sankila R, Isoniemi H. Risk of malignant neoplasms after liver transplantation: a population-based study. *Liver Transpl* 2008; **14**: 1428-1436 [PMID: 18825704 DOI: 10.1002/lt.21475]

10 **Jiang Y**, Villeneuve PJ, Fenton SS, Schaubel DE, Lilly L, Mao Y. Liver transplantation and subsequent risk of cancer: findings from a Canadian cohort study. *Liver Transpl* 2008; **14**: 1588-1597 [PMID: 18975293 DOI: 10.1002/lt.21554]

11 **Ettorre GM**, Piselli P, Galatioto L, Rendina M, Nudo F, Sforza D, Miglioresi L, Fantola G, Cimaglia C, Vennarecci G, Vizzini GB, Di Leo A, Rossi M, Tisone G, Zamboni F, Santoro R, Agresta A, Puro V, Serraino D. De novo malignancies following liver transplantation: results from a multicentric study in central and southern Italy, 1990-2008. *Transplant Proc* 2013; **45**: 2729-2732 [PMID: 24034034 DOI: 10.1016/j.transproceed.2013.07.050]

12 **Watt KD**, Pedersen RA, Kremers WK, Heimbach JK, Sanchez W, Gores GJ. Long-term probability of and mortality from de novo malignancy after liver transplantation. *Gastroenterology* 2009; **137**: 2010-2017 [PMID: 19766646 DOI: 10.1053/j.gastro.2009.08.070]

13 **Penn I**. Cancer in the immunosuppressed organ recipient. *Transplant Proc* 1991; **23**: 1771-1772 [PMID: 2053149]

14 **Engels EA**, Pfeiffer RM, Fraumeni JF, Kasiske BL, Israni AK, Snyder JJ, Wolfe RA, Goodrich NP, Bayakly AR, Clarke CA, Copeland G, Finch JL, Fleissner ML, Goodman MT, Kahn A, Koch L, Lynch CF, Madeleine MM, Pawlish K, Rao C, Williams MA, Castenson D, Curry M, Parsons R, Fant G, Lin M. Spectrum of cancer risk among US solid organ transplant recipients. *JAMA* 2011; **306**: 1891-1901 [PMID: 22045767 DOI: 10.1001/jama.2011.1592]

15 **Adami J**, Gäbel H, Lindelöf B, Ekström K, Rydh B, Glimelius B, Ekbom A, Adami HO, Granath F. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. *Br J Cancer* 2003; **89**: 1221-1227 [PMID: 14520450 DOI: 10.1038/sj.bjc.6601219]

16 **Collett D**, Mumford L, Banner NR, Neuberger J, Watson C. Comparison of the incidence of malignancy in recipients of different types of organ: a UK Registry audit. *Am J Transplant* 2010; **10**: 1889-1896 [PMID: 20659094 DOI: 10.1111/j.1600-6143.20]

17 **Baccarani U**, Piselli P, Serraino D, Adani GL, Lorenzin D, Gambato M, Buda A, Zanus G, Vitale A, De Paoli A, Cimaglia C, Bresadola V, Toniutto P, Risaliti A, Cillo U, Bresadola F, Burra P. Comparison of de novo tumours after liver transplantation with incidence rates from Italian cancer registries. *Dig Liver Dis* 2010; **42**: 55-60 [PMID: 19497797 DOI: 10.1016/j.dld.2009.04.017]

18 **Finkenstedt A**, Graziadei IW, Oberaigner W, Hilbe W, Nachbaur K, Mark W, Margreiter R, Vogel W. Extensive surveillance promotes early diagnosis and improved survival of de novo malignancies in liver transplant recipients. *Am J Transplant* 2009; **9**: 2355-2361 [PMID: 19663894 DOI: 10.1111/j.1600-6143.2009.02766.x]

19 **Dunn GP**, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. *Immunity* 2004; **21**: 137-148 [PMID: 15308095 DOI: 10.1016/j.immuni.2004.07.017]

20 **Na R**, Grulich AE, Meagher NS, McCaughan GW, Keogh AM, Vajdic CM. Comparison of de novo cancer incidence in Australian liver, heart and lung transplant recipients. *Am J Transplant* 2013; **13**: 174-183 [PMID: 23094788 DOI: 10.1111/j.1600-6143.2012.04302.x]

21 **Vivarelli M**, Cucchetti A, La Barba G, Ravaioli M, Del Gaudio M, Lauro A, Grazi GL, Pinna AD. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence. *Ann Surg* 2008; **248**: 857-862 [PMID: 18948815 DOI: 10.1097/SLA.0b013e3181896278]

22 **Rodríguez-Perálvarez M**, Tsochatzis E, Naveas MC, Pieri G, García-Caparrós C, O'Beirne J, Poyato-González A, Ferrín-Sánchez G, Montero-Álvarez JL, Patch D, Thorburn D, Briceño J, De la Mata M, Burroughs AK. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. *J Hepatol* 2013; **59**: 1193-1199 [PMID: 23867318 DOI: 10.1016/j.jhep.2013.07.012]

23 **Weischer M**, Röcken M, Berneburg M. Calcineurin inhibitors and rapamycin: cancer protection or promotion? *Exp Dermatol* 2007; **16**: 385-393 [PMID: 17437481 DOI: 10.1111/j.1600-0625.2007.00555.x]

24 **Wimmer CD**, Angele MK, Schwarz B, Pratschke S, Rentsch M, Khandoga A, Guba M, Jauch KW, Bruns C, Graeb C. Impact of cyclosporine versus tacrolimus on the incidence of de novo malignancy following liver transplantation: a single center experience with 609 patients. *Transpl Int* 2013; **26**: 999-1006 [PMID: 23952102 DOI: 10.1111/tri.12165]

25 **Kelly DM**, Emre S, Guy SR, Miller CM, Schwartz ME, Sheiner PA. Liver transplant recipients are not at increased risk for nonlymphoid solid organ tumors. *Cancer* 1998; **83**: 1237-1243 [PMID: 8693547 DOI: 10.1002/(SICI)1097-0142(19980915)83]

26 **Marqués Medina E**, Jiménez Romero C, Gómez de la Cámara A, Rota Bernal A, Manrique Municio A, Moreno González E. Malignancy after liver transplantation: cumulative risk for development. *Transplant Proc* 2009; **41**: 2447-2449 [PMID: 19715947 DOI: 10.1016/j.transproceed.2009.06.153]

27 **Tjon AS**, Sint Nicolaas J, Kwekkeboom J, de Man RA, Kazemier G, Tilanus HW, Hansen BE, van der Laan LJ, Tha-In T, Metselaar HJ. Increased incidence of early de novo cancer in liver graft recipients treated with cyclosporine: an association with C2 monitoring and recipient age. *Liver Transpl* 2010; **16**: 837-846 [PMID: 20583092 DOI: 10.1002/lt.22064]

28 **Jonas S**, Rayes N, Neumann U, Neuhaus R, Bechstein WO, Guckelberger O, Tullius SG, Serke S, Neuhaus P. De novo malignancies after liver transplantation using tacrolimus-based protocols or cyclosporine-based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte globulin. *Cancer* 1997; **80**: 1141-1150 [PMID: 9305716 DOI: 10.1002/(SICI)1097-0142(19970915)80]

29 **Geissler EK**, Schlitt HJ, Thomas G. mTOR, cancer and transplantation. *Am J Transplant* 2008; **8**: 2212-2218 [PMID: 18785960 DOI: 10.1111/j.1600-6143.2008.02391.x]

30 **Vivarelli M**, Dazzi A, Zanello M, Cucchetti A, Cescon M, Ravaioli M, Del Gaudio M, Lauro A, Grazi GL, Pinna AD. Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma. *Transplantation* 2010; **89**: 227-231 [PMID: 20098287 DOI: 10.1097/TP.0b013e3181c3c540]

31 **Chinnakotla S**, Davis GL, Vasani S, Kim P, Tomiyama K, Sanchez E, Onaca N, Goldstein R, Levy M, Klintmalm GB. Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation. *Liver Transpl* 2009; **15**: 1834-1842 [PMID: 19938137 DOI: 10.1002/lt.21953]

32 **Bilbao I**, Sapisochin G, Dopazo C, Lazaro JL, Pou L, Castells L, Caralt M, Blanco L, Gantxegi A, Margarit C, Charco R. Indications and management of everolimus after liver transplantation. *Transplant Proc* 2009; **41**: 2172-2176 [PMID: 19715864 DOI: 10.1016/j.transproceed.2009.06.087]

33 **Jiménez-Romero C**, Manrique A, Marqués E, Calvo J, Sesma AG, Cambra F, Abradelo M, Sterup RM, Olivares S, Justo I, Colina F, Moreno E. Switching to sirolimus monotherapy for de novo tumors after liver transplantation. A preliminary experience. *Hepatogastroenterology* 2011; **58**: 115-121 [PMID: 21510297]

34 **Kauffman HM**, Cherikh WS, Cheng Y, Hanto DW, Kahan BD. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. *Transplantation* 2005; **80**: 883-889 [PMID: 16249734 DOI: 10.1097/01.TP.0000184006.43152.8D]

35 **Menon KV**, Hakeem AR, Heaton ND. Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma. *Aliment Pharmacol Ther* 2013; **37**: 411-419 [PMID: 23278125 DOI: 10.1111/apt.12185]

36 **Benlloch S**, Berenguer M, Prieto M, Moreno R, San Juan F, Rayón M, Mir J, Segura A, Berenguer J. De novo internal neoplasms after liver transplantation: increased risk and aggressive behavior in recent years? *Am J Transplant* 2004; **4**: 596-604 [PMID: 15023152 DOI: 10.1111/j.1600-6143.2004.00380.x]

37 **Tressler RJ**, Garvin LJ, Slate DL. Anti-tumor activity of mycophenolate mofetil against human and mouse tumors in vivo. *Int J Cancer* 1994; **57**: 568-573 [PMID: 8181860 DOI: 10.1002/ijc.2910570421]

38 **Robson R**, Cecka JM, Opelz G, Budde M, Sacks S. Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. *Am J Transplant* 2005; **5**: 2954-2960 [PMID: 16303010 DOI: 10.1111/j.1600-6143.2005.01125.x]

39 **Safaeian M**, Robbins HA, Berndt SI, Lynch CF, Fraumeni JF, Engels EA. Risk of Colorectal Cancer After Solid Organ Transplantation in the United States. *Am J Transplant* 2016; **16**: 960-967 [PMID: 26731613 DOI: 10.1111/ajt.13549]

40 **Yao FY**, Gautam M, Palese C, Rebres R, Terrault N, Roberts JP, Peters MG. De novo malignancies following liver transplantation: a case-control study with long-term follow-up. *Clin Transplant* 2006; **20**: 617-623 [PMID: 16968488 DOI: 10.1111/j.1399-0012.2006.00527.x]

41 **Schulz TF**. Cancer and viral infections in immunocompromised individuals. *Int J Cancer* 2009; **125**: 1755-1763 [PMID: 19588503 DOI: 10.1002/ijc.24741]

42 **Piselli P**, Busnach G, Fratino L, Citterio F, Ettorre GM, De Paoli P, Serraino D. De novo malignancies after organ transplantation: focus on viral infections. *Curr Mol Med* 2013; **13**: 1217-1227 [PMID: 23278452 DOI: 10.2174/15665240113139990041]

43 **Parker A**, Bowles K, Bradley JA, Emery V, Featherstone C, Gupte G, Marcus R, Parameshwar J, Ramsay A, Newstead C. Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients - BCSH and BTS Guidelines. *Br J Haematol* 2010; **149**: 675-692 [PMID: 20408847 DOI: 10.1111/j.1365-2141.20]

44 **Xiol X**, Guardiola J, Menendez S, Lama C, Figueras J, Marcoval J, Serrano T, Botargues JM, Mañer M, Rota R. Risk factors for development of de novo neoplasia after liver transplantation. *Liver Transpl* 2001; **7**: 971-975 [PMID: 11699033 DOI: 10.1053/jlts.2001.28744]

45 **Oo YH**, Gunson BK, Lancashire RJ, Cheng KK, Neuberger JM. Incidence of cancers following orthotopic liver transplantation in a single center: comparison with national cancer incidence rates for England and Wales. *Transplantation* 2005; **80**: 759-764 [PMID: 16210962 DOI: 10.1097/01.TP.0000173775.16579.18]

46 **Herrero JI**, Lucena JF, Quiroga J, Sangro B, Pardo F, Rotellar F, Alvárez-Cienfuegos J, Prieto J. Liver transplant recipients older than 60 years have lower survival and higher incidence of malignancy. *Am J Transplant* 2003; **3**: 1407-1412 [PMID: 14525602]

47 **Maggi U**, Consonni D, Manini MA, Gatti S, Cuccaro F, Donato F, Conte G, Bertazzi PA, Rossi G. Early and late de novo tumors after liver transplantation in adults: the late onset of bladder tumors in men. *PLoS One* 2013; **8**: e65238 [PMID: 23785414 DOI: 10.1371/journal.pone.0065238]

48 **Holick MF**. High prevalence of vitamin D inadequacy and implications for health. *Mayo Clin Proc* 2006; **81**: 353-373 [PMID: 16529140 DOI: 10.4065/81.3.353]

49 **Seitz HK**, Stickel F. Molecular mechanisms of alcohol-mediated carcinogenesis. *Nat Rev Cancer* 2007; **7**: 599-612 [PMID: 17646865 DOI: 10.1038/nrc2191]

50 **Carbone D**. Smoking and cancer. *Am J Med* 1992; **93**: 13S-17S [PMID: 1496998 DOI: 10.1016/0002-9343(92)90621-H]

51 **Dumortier J**, Guillaud O, Adham M, Boucaud C, Delafosse B, Bouffard Y, Paliard P, Scoazec JY, Boillot O. Negative impact of de novo malignancies rather than alcohol relapse on survival after liver transplantation for alcoholic cirrhosis: a retrospective analysis of 305 patients in a single center. *Am J Gastroenterol* 2007; **102**: 1032-1041 [PMID: 17313502 DOI: 10.1111/j.1572-0241.2007.01079.x]

52 **Jiménez C**, Marqués E, Loinaz C, Romano DR, Gómez R, Meneu JC, Hernández-Vallejo G, Alonso O, Abradelo M, Garcia I, Moreno E. Upper aerodigestive tract and lung tumors after liver transplantation. *Transplant Proc* 2003; **35**: 1900-1901 [PMID: 12962840 DOI: 10.1016/S0041-1345(03)00641-9]

53 **Zanus G**, Carraro A, Vitale A, Gringeri E, D'Amico F, Valmasoni M, D'Amico FE, Brolese A, Boccagni P, Neri D, Srsen N, Burra P, Feltracco P, Bonsignore P, Scopelliti M, Cillo U. Alcohol abuse and de novo tumors in liver transplantation. *Transplant Proc* 2009; **41**: 1310-1312 [PMID: 19460548 DOI: 10.1016/j.transproceed.2009.03.055]

54 **Jiménez C**, Rodríguez D, Marqués E, Loinaz C, Alonso O, Hernández-Vallejo G, Marín L, Rodríguez F, García I, Moreno E. De novo tumors after orthotopic liver transplantation. *Transplant Proc* 2002; **34**: 297-298 [PMID: 11959293 DOI: 10.1016/S0041-1345(01)02770-1]

55 **Mashberg A**, Boffetta P, Winkelman R, Garfinkel L. Tobacco smoking, alcohol drinking, and cancer of the oral cavity and oropharynx among U.S. veterans. *Cancer* 1993; **72**: 1369-1375 [PMID: 8339227 DOI: 10.1002/1097-0142(19930815)72]

56 **Leithead JA**, Ferguson JW, Hayes PC. Smoking-related morbidity and mortality following liver transplantation. *Liver Transpl* 2008; **14**: 1159-1164 [PMID: 18668649 DOI: 10.1002/lt.21471]

57 **Castelli E**, Hrelia P, Maffei F, Fimognari C, Foschi FG, Caputo F, Cantelli-Forti G, Stefanini GF, Gasbarrini G. Indicators of genetic damage in alcoholics: reversibility after alcohol abstinence. *Hepatogastroenterology* 1999; **46**: 1664-1668 [PMID: 10430317]

58 **Castellsagué X**, Muñoz N, De Stefani E, Victora CG, Quintana MJ, Castelletto R, Rolón PA. Smoking and drinking cessation and risk of esophageal cancer (Spain). *Cancer Causes Control* 2000; **11**: 813-818 [PMID: 11075870 DOI: 10.1023/A: 1008984922453]

59 **Danpanich E**, Kasiske BL. Risk factors for cancer in renal transplant recipients. *Transplantation* 1999; **68**: 1859-1864 [PMID: 10628765 DOI: 10.1097/00007890-199912270-00008]

60 **Webster AC**, Craig JC, Simpson JM, Jones MP, Chapman JR. Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: a cohort study of 15,183 recipients. *Am J Transplant* 2007; **7**: 2140-2151 [PMID: 17640312 DOI: 10.1111/j.1600-6143.2007.01908.x]

61 **Frezza EE**, Fung JJ, van Thiel DH. Non-lymphoid cancer after liver transplantation. *Hepatogastroenterology* 1997; **44**: 1172-1181 [PMID: 9261620]

62 **Bouwes Bavinck JN**, Claas FH, Hardie DR, Green A, Vermeer BJ, Hardie IR. Relation between HLA antigens and skin cancer in renal transplant recipients in Queensland, Australia. *J Invest Dermatol* 1997; **108**: 708-711 [PMID: 9129219 DOI: 10.1111/1523-1747.ep12292086]

63 **Hofbauer GF**, Bouwes Bavinck JN, Euvrard S. Organ transplantation and skin cancer: basic problems and new perspectives. *Exp Dermatol* 2010; **19**: 473-482 [PMID: 20482618 DOI: 10.1111/j.1600-0625.20]

64 **Braakhuis BJ**, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. *Cancer Res* 2003; **63**: 1727-1730 [PMID: 12702551]

65 **Jonason AS**, Kunala S, Price GJ, Restifo RJ, Spinelli HM, Persing JA, Leffell DJ, Tarone RE, Brash DE. Frequent clones of p53-mutated keratinocytes in normal human skin. *Proc Natl Acad Sci USA* 1996; **93**: 14025-14029 [PMID: 8943054]

66 **Herrero JI**, España A, Quiroga J, Sangro B, Pardo F, Alvárez-Cienfuegos J, Prieto J. Nonmelanoma skin cancer after liver transplantation. Study of risk factors. *Liver Transpl* 2005; **11**: 1100-1106 [PMID: 16123952 DOI: 10.1002/lt.20525]

67 **Park HW**, Hwang S, Ahn CS, Kim KH, Moon DB, Ha TY, Song GW, Jung DH, Park GC, Namgoong JM, Yoon SY, Park CS, Park YH, Lee HJ, Lee SG. De novo malignancies after liver transplantation: incidence comparison with the Korean cancer registry. *Transplant Proc* 2012; **44**: 802-805 [PMID: 22483500 DOI: 10.1016/j.transproceed.2012.01.027]

68 **Sanaei AK**, Aliakbarian M, Kazemi K, Nikeghbalian S, Shamsaeefar A, Mehdi SH, Bahreini A, Dehghani SM, Geramizadeh B, Malekhosseini SA. De novo malignancy after liver transplant. *Exp Clin Transplant* 2015; **13**: 163-166 [PMID: 24844266 DOI: 10.6002/ect.2013.0135]

69 **Yu S**, Gao F, Yu J, Yan S, Wu J, Zhang M, Wang W, Zheng S. De novo cancers following liver transplantation: a single center experience in China. *PLoS One* 2014; **9**: e85651 [PMID: 24475047 DOI: 10.1371/journal.pone.0085651]

70 **Euvrard S**, Kanitakis J, Claudy A. Skin cancers after organ transplantation. *N Engl J Med* 2003; **348**: 1681-1691 [PMID: 12711744 DOI: 10.1056/NEJMra022137]

71 **Otley CC**. Organization of a specialty clinic to optimize the care of organ transplant recipients at risk for skin cancer. *Dermatol Surg* 2000; **26**: 709-712 [PMID: 10886290 DOI: 10.1046/j.1524-4725.2000.00091.x]

72 **Euvrard S**, Ulrich C, Lefrancois N. Immunosuppressants and skin cancer in transplant patients: focus on rapamycin. *Dermatol Surg* 2004; **30**: 628-633 [PMID: 15061847 DOI: 10.1111/j.1524-4725.2004.30148.x]

73 **Guba M**, Graeb C, Jauch KW, Geissler EK. Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation. *Transplantation* 2004; **77**: 1777-1782 [PMID: 15223891 DOI: 10.1097/01.TP.0000120181.89206.54]

74 **Hojo M**, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M, Shimbo T, Suthanthiran M. Cyclosporine induces cancer progression by a cell-autonomous mechanism. *Nature* 1999; **397**: 530-534 [PMID: 10028970 DOI: 10.1038/17401]

75 **de Graaf YG**, Rebel H, Elghalbzouri A, Cramers P, Nellen RG, Willemze R, Bouwes Bavinck JN, de Gruijl FR. More epidermal p53 patches adjacent to skin carcinomas in renal transplant recipients than in immunocompetent patients: the role of azathioprine. *Exp Dermatol* 2008; **17**: 349-355 [PMID: 17979968 DOI: 10.1111/j.1600-0625.2007.00651.x]

76 **O'Donovan P**, Perrett CM, Zhang X, Montaner B, Xu YZ, Harwood CA, McGregor JM, Walker SL, Hanaoka F, Karran P. Azathioprine and UVA light generate mutagenic oxidative DNA damage. *Science* 2005; **309**: 1871-1874 [PMID: 16166520 DOI: 10.1126/science.1114233]

77 **Duncan FJ**, Wulff BC, Tober KL, Ferketich AK, Martin J, Thomas-Ahner JM, Allen SD, Kusewitt DF, Oberyszyn TM, Vanbuskirk AM. Clinically relevant immunosuppressants influence UVB-induced tumor size through effects on inflammation and angiogenesis. *Am J Transplant* 2007; **7**: 2693-2703 [PMID: 17941958 DOI: 10.1111/j.1600-6143.2007.02004.x]

78 **Tessari G**, Naldi L, Boschiero L, Nacchia F, Fior F, Forni A, Rugiu C, Faggian G, Sassi F, Gotti E, Fiocchi R, Talamini G, Girolomoni G. Incidence and clinical predictors of a subsequent nonmelanoma skin cancer in solid organ transplant recipients with a first nonmelanoma skin cancer: a multicenter cohort study. *Arch Dermatol* 2010; **146**: 294-299 [PMID: 20231501 DOI: 10.1001/archdermatol.2009.377]

79 **Euvrard S**, Morelon E, Rostaing L, Goffin E, Brocard A, Tromme I, Broeders N, del Marmol V, Chatelet V, Dompmartin A, Kessler M, Serra AL, Hofbauer GF, Pouteil-Noble C, Campistol JM, Kanitakis J, Roux AS, Decullier E, Dantal J. Sirolimus and secondary skin-cancer prevention in kidney transplantation. *N Engl J Med* 2012; **367**: 329-339 [PMID: 22830463 DOI: 10.1056/NEJMoa1204166]

80 **Serraino D**, Piselli P, Scognamiglio P. Viral infections and cancer: epidemiological aspects. *J Biol Regul Homeost Agents* 2001; **15**: 224-228 [PMID: 11693428]

81 **Dukers NH**, Rezza G. Human herpesvirus 8 epidemiology: what we do and do not know. *AIDS* 2003; **17**: 1717-1730 [PMID: 12891058 DOI: 10.1097/01.aids.0000076337.42412.86]

82 **Kremers WK**, Devarbhavi HC, Wiesner RH, Krom RAF, Macon WR, Habermann TM. Post-Transplant Lymphoproliferative Disorders Following Liver Transplantation: Incidence, Risk Factors and Survival. *Am J Transplantat* 2006; **6** (5p1): 1017-1024 [DOI: 10.1111/j.1600-6143.2006.01294.x]

83 **LaCasce AS**. Post-transplant lymphoproliferative disorders. *Oncologist* 2006; **11**: 674-680 [PMID: 16794246 DOI: 10.1634/theoncologist.11-6-674]

84 **Taylor AL**, Marcus R, Bradley JA. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. *Crit Rev Oncol Hematol* 2005; **56**: 155-167 [PMID: 15979320]

85 **Knight JS**, Tsodikov A, Cibrik DM, Ross CW, Kaminski MS, Blayney DW. Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center. *J Clin Oncol* 2009; **27**: 3354-3362 [PMID: 19451438 DOI: 10.1200/jco.2008.20.0857]

86 **Walker RC**, Marshall WF, Strickler JG, Wiesner RH, Velosa JA, Habermann TM, McGregor CG, Paya CV. Pretransplantation assessment of the risk of lymphoproliferative disorder. *Clin Infect Dis* 1995; **20**: 1346-1353 [PMID: 7620022 DOI: 10.1093/clinids/20.5.1346]

87 **Newell KA**, Alonso EM, Whitington PF, Bruce DS, Millis JM, Piper JB, Woodle ES, Kelly SM, Koeppen H, Hart J, Rubin CM, Thistlethwaite JR. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression. *Transplantation* 1996; **62**: 370-375 [PMID: 8779685 DOI: 10.1097/00007890-199608150-00012]

88 **Saha A**, Robertson ES. Epstein-Barr virus-associated B-cell lymphomas: pathogenesis and clinical outcomes. *Clin Cancer Res* 2011; **17**: 3056-3063 [PMID: 21372216 DOI: 10.1158/1078-0432.ccr-10-2578]

89 **Collins MH**, Montone KT, Leahey AM, Hodinka RL, Salhany KE, Belchis DA, Tomaszewski JE. Autopsy pathology of pediatric posttransplant lymphoproliferative disorder. *Pediatrics* 2001; **107**: E89 [PMID: 11389287 DOI: 10.1542/peds.107.6.e89]

90 **Niederman JC**, Evans AS, Subrahmanyan L, McCollum RW. Prevalence, incidence and persistence of EB virus antibody in young adults. *N Engl J Med* 1970; **282**: 361-365 [PMID: 4312365 DOI: 10.1056/nejm197002122820704]

91 **Dotti G**, Fiocchi R, Motta T, Gamba A, Gotti E, Gridelli B, Borleri G, Manzoni C, Viero P, Remuzzi G, Barbui T, Rambaldi A. Epstein-Barr virus-negative lymphoproliferate disorders in long-term survivors after heart, kidney, and liver transplant. *Transplantation* 2000; **69**: 827-833 [PMID: 10755535 DOI: 10.1097/00007890-200003150-00027]

92 **Duvoux C**, Pageaux GP, Vanlemmens C, Roudot-Thoraval F, Vincens-Rolland AL, Hézode C, Gaulard P, Miguet JP, Larrey D, Dhumeaux D, Cherqui D. Risk factors for lymphoproliferative disorders after liver transplantation in adults: an analysis of 480 patients. *Transplantation* 2002; **74**: 1103-1109 [PMID: 12438954 DOI: 10.1097/00007890-200210270-00008]

93 **Hézode C**, Duvoux C, Germanidis G, Roudot-Thoraval F, Vincens AL, Gaulard P, Cherqui D, Pawlotsky JM, Dhumeaux D. Role of hepatitis C virus in lymphoproliferative disorders after liver transplantation. *Hepatology* 1999; **30**: 775-778 [PMID: 10462385 DOI: 10.1002/hep.510300314]

94 **Fernández MC**, Bes D, De Dávila M, López S, Cambaceres C, Dip M, Imventarza O. Post-transplant lymphoproliferative disorder after pediatric liver transplantation: characteristics and outcome. *Pediatr Transplant* 2009; **13**: 307-310 [PMID: 18346039 DOI: 10.1111/j.1399-3046.2008.00914.x]

95 **Leblond V**, Dhedin N, Mamzer Bruneel MF, Choquet S, Hermine O, Porcher R, Nguyen Quoc S, Davi F, Charlotte F, Dorent R, Barrou B, Vernant JP, Raphael M, Levy V. Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. *J Clin Oncol* 2001; **19**: 772-778 [PMID: 11157030]

96 **Maecker B**, Jack T, Zimmermann M, Abdul-Khaliq H, Burdelski M, Fuchs A, Hoyer P, Koepf S, Kraemer U, Laube GF, Müller-Wiefel DE, Netz H, Pohl M, Toenshoff B, Wagner HJ, Wallot M, Welte K, Melter M, Offner G, Klein C. CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation. *J Clin Oncol* 2007; **25**: 4902-4908 [PMID: 17971586 DOI: 10.1200/jco.2006.DOI: ]

97 **Evens AM**, David KA, Helenowski I, Nelson B, Kaufman D, Kircher SM, Gimelfarb A, Hattersley E, Mauro LA, Jovanovic B, Chadburn A, Stiff P, Winter JN, Mehta J, Van Besien K, Gregory S, Gordon LI, Shammo JM, Smith SE, Smith SM. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. *J Clin Oncol* 2010; **28**: 1038-1046 [PMID: 20085936 DOI: 10.1200/jco.2009.25.4961]

98 **Richendollar BG**, Tsao RE, Elson P, Jin T, Steinle R, Pohlman B, Hsi ED. Predictors of outcome in post-transplant lymphoproliferative disorder: an evaluation of tumor infiltrating lymphocytes in the context of clinical factors. *Leuk Lymphoma* 2009; **50**: 2005-2012 [PMID: 19860626 DOI: 10.3109/10428190903315713]

99 **Zimmermann H**, Oschlies I, Fink S, Pott C, Neumayer HH, Lehmkuhl H, Hauser IA, Dreyling M, Kneba M, Gärtner B, Anagnostopoulos I, Riess H, Klapper W, Trappe RU. Plasmablastic posttransplant lymphoma: cytogenetic aberrations and lack of Epstein-Barr virus association linked with poor outcome in the prospective German Posttransplant Lymphoproliferative Disorder Registry. *Transplantation* 2012; **93**: 543-550 [PMID: 22234349 DOI: 10.1097/TP.0b013e318242162d]

100 **Liu Q**, Yan L, Xu C, Gu A, Zhao P, Jiang ZY. Increased incidence of head and neck cancer in liver transplant recipients: a meta-analysis. *BMC Cancer* 2014; **14**: 776 [PMID: 25338638 DOI: 10.1186/1471-2407-14-776]

101 **Chak E**, Saab S. Risk factors and incidence of de novo malignancy in liver transplant recipients: a systematic review. *Liver Int* 2010; **30**: 1247-1258 [PMID: 20602682 DOI: 10.1111/j.1478-3231.20]

102 **Herrero JI**, Pardo F, D'Avola D, Alegre F, Rotellar F, Iñarrairaegui M, Martí P, Sangro B, Quiroga J. Risk factors of lung, head and neck, esophageal, and kidney and urinary tract carcinomas after liver transplantation: the effect of smoking withdrawal. *Liver Transpl* 2011; **17**: 402-408 [PMID: 21445923 DOI: 10.1002/lt.22247]

103 **Vallejo GH**, Romero CJ, de Vicente JC. Incidence and risk factors for cancer after liver transplantation. *Crit Rev Oncol Hematol* 2005; **56**: 87-99 [PMID: 15979889 DOI: 10.1016/j.critrevonc.2004.12.011]

104 **Bleday R**, Lee E, Jessurun J, Heine J, Wong WD. Increased risk of early colorectal neoplasms after hepatic transplant in patients with inflammatory bowel disease. *Dis Colon Rectum* 1993; **36**: 908-912 [PMID: 8404380 DOI: 10.1007/BF02050624]

105 **Fabia R**, Levy MF, Testa G, Obiekwe S, Goldstein RM, Husberg BS, Gonwa TA, Klintmalm GB. Colon carcinoma in patients undergoing liver transplantation. *Am J Surg* 1998; **176**: 265-269 [PMID: 9776156 DOI: 10.1016/S0002-9610(98)00141-X]

106 **Vera A**, Gunson BK, Ussatoff V, Nightingale P, Candinas D, Radley S, Mayer A, Buckels JA, McMaster P, Neuberger J, Mirza DF. Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. *Transplantation* 2003; **75**: 1983-1988 [PMID: 12829898 DOI: 10.1097/01.tp.0000058744.34965.38]

107 **Buell JF**, Papaconstantinou HT, Skalow B, Hanaway MJ, Alloway RR, Woodle ES. De novo colorectal cancer: five-year survival is markedly lower in transplant recipients compared with the general population. *Transplant Proc* 2005; **37**: 960-961 [PMID: 15848590 DOI: 10.1016/j.transproceed.2004.12.122]

108 **Johnson EE**, Leverson GE, Pirsch JD, Heise CP. A 30-year analysis of colorectal adenocarcinoma in transplant recipients and proposal for altered screening. *J Gastrointest Surg* 2007; **11**: 272-279 [PMID: 17458597 DOI: 10.1007/s11605-007-0084-4]

109 **Miao Y**, Everly JJ, Gross TG, Tevar AD, First MR, Alloway RR, Woodle ES. De novo cancers arising in organ transplant recipients are associated with adverse outcomes compared with the general population. *Transplantation* 2009; **87**: 1347-1359 [PMID: 19424035 DOI: 10.1097/TP.0b013e3181a238f6]

110 **Herrero JI**, Alegre F, Quiroga J, Pardo F, Iñarrairaegui M, Sangro B, Rotellar F, Montiel C, Prieto J. Usefulness of a program of neoplasia surveillance in liver transplantation. A preliminary report. *Clin Transplant* 2009; **23**: 532-536 [PMID: 19681977 DOI: 10.1111/j.1399-0012.2008.00927.x]

111 **Herrero JI**, Bastarrika G, D'Avola D, Montes U, Pueyo J, Iñarrairaegui M, Pardo F, Quiroga J, Zulueta J. Lung cancer screening with low-radiation dose computed tomography after liver transplantation. *Ann Transplant* 2013; **18**: 587-592 [PMID: 24165787 DOI: 10.12659/aot.884021]

112 **Farge D**, Lebbé C, Marjanovic Z, Tuppin P, Mouquet C, Peraldi MN, Lang P, Hiesse C, Antoine C, Legendre C, Bedrossian J, Gagnadoux MF, Loirat C, Pellet C, Sheldon J, Golmard JL, Agbalika F, Schulz TF. Human herpes virus-8 and other risk factors for Kaposi's sarcoma in kidney transplant recipients. Groupe Cooperatif de Transplantation d' Ile de France (GCIF). *Transplantation* 1999; **67**: 1236-1242 [PMID: 10342315 DOI: 10.1097/00007890-199905150-00007]

113 **Ulrich C**, Jürgensen JS, Degen A, Hackethal M, Ulrich M, Patel MJ, Eberle J, Terhorst D, Sterry W, Stockfleth E. Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. *Br J Dermatol* 2009; **161** Suppl 3: 78-84 [PMID: 19775361 DOI: 10.1111/j.1365-2133.2009.09453.x]

114 **Aguilera J**, de Gálvez MV, Sánchez-Roldán C, Herrera-Ceballos E. New advances in protection against solar ultraviolet radiation in textiles for summer clothing. *Photochem Photobiol* 2014; **90**: 1199-1206 [PMID: 24861801 DOI: 10.1111/php.12292]

115 **Schnitzbauer AA**, Zuelke C, Graeb C, Rochon J, Bilbao I, Burra P, de Jong KP, Duvoux C, Kneteman NM, Adam R, Bechstein WO, Becker T, Beckebaum S, Chazouillères O, Cillo U, Colledan M, Fändrich F, Gugenheim J, Hauss JP, Heise M, Hidalgo E, Jamieson N, Königsrainer A, Lamby PE, Lerut JP, Mäkisalo H, Margreiter R, Mazzaferro V, Mutzbauer I, Otto G, Pageaux GP, Pinna AD, Pirenne J, Rizell M, Rossi G, Rostaing L, Roy A, Turrion VS, Schmidt J, Troisi RI, van Hoek B, Valente U, Wolf P, Wolters H, Mirza DF, Scholz T, Steininger R, Soderdahl G, Strasser SI, Jauch KW, Neuhaus P, Schlitt HJ, Geissler EK. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. *BMC Cancer* 2010; **10**: 190 [PMID: 20459775 DOI: 10.1186/1471-2407-10-190]

116 **Galve ML**, Cuervas-Mons V, Figueras J, Herrero I, Mata M, Clemente G, Prieto M, Margarit C, Bernardos A, Casafont F. Incidence and outcome of de novo malignancies after liver transplantation. *Transplant Proc* 1999; **31**: 1275-1277 [PMID: 10083569 DOI: 10.1016/S0041-1345(98)01994-0]

117 **Antinucci F**, Anders M, Orozco F, Mella J, Cobos M, McCormack L, Mastai R. [De novo malignant tumors following liver transplantation. A single-center experience in Argentina]. *Medicina* (B Aires) 2015; **75**: 18-22 [PMID: 25637895]

118 **Na R**, Grulich AE, Meagher NS, McCaughan GW, Keogh AM, Vajdic CM. De novo cancer-related death in Australian liver and cardiothoracic transplant recipients. *Am J Transplant* 2013; **13**: 1296-1304 [PMID: 23464511 DOI: 10.1111/ajt.12192]

119 **Ducroux E**, Boillot O, Ocampo MA, Decullier E, Roux A, Dumortier J, Kanitakis J, Jullien D, Euvrard S. Skin cancers after liver transplantation: retrospective single-center study on 371 recipients. *Transplantation* 2014; **98**: 335-340 [PMID: 24621534 DOI: 10.1097/TP.0000000000000051]

120 **Mithoefer AB**, Supran S, Freeman RB. Risk factors associated with the development of skin cancer after liver transplantation. *Liver Transpl* 2002; **8**: 939-944 [PMID: 12360438 DOI: 10.1053/jlts.2002.35551]

 **P-Reviewer:** **Dehghani SM, Keller F,** Kin T **S-Editor:** Qi Y **L-Editor: E-Editor:**

**Table 1 Summary of study characteristics and reported incidence of *de novo* malignancy post liver transplantation in large series**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Study by first author**  | **Year published** |  **Country of study center**  | **Study period** | **Number of liver transplant recipients** | **4Duration of follow-up (yr)**  | **4Age at transplant in patients with *de novo* malignancy (yr)** | **Proportion of males with *de novo* malignancy**  | **4Interval to *de novo* malignancy (years)** | **Overall incidence of *de novo* malignancy (number of patients)** | **5/ 10/ 15 and 20 year incidence of *de novo* malignancy** |  **Estimated overall risk relative to control population**  |
|  Jonas *et al*[[28](#_ENREF_28)] | 1997 |  Germany  | 1988-1994 | 458 | 4.2 | 46 ± 14 | 48% | 3.6 | 7.2% (33) | 14.6%/-/ -/ - | - |
|  Jain *et al*[[3](#_ENREF_28)] | 1998 |  United States  | 1996-2006 | 1000 | 6.5 ± 1 | Approx. 56 | 77% | 3 | 5.7% (57) | - | SIR calculated for specific cancer types |
|  Kelly *et al*[[25](#_ENREF_28)] | 1998 |  United Kingdom  | 1988-1996 | 888 | - | Approx. 52 | 46% | 2 ± 1.5 | **2**4.4%(29) | - | - |
|  Galve *et al*[[116](#_ENREF_28)] | 1999 |  Spain  | 1984-1997 | 1827 | - | - | - | 2.5 ± 1.8 | 3.8% (70) | - | - |
|  Haagsma *et al*[[8](#_ENREF_28)] | 2001 |  Netherlands  | 1979-1996 | 174 | 5.1 | Approx. 49 | 29% | 5.9 | 12% (21) | 6%/ 20%/ 55%/ - | RR= 4.3 (95%CI= 2.4–7.1) |
|  Sanchez *et al*[[5](#_ENREF_28)] | 2002 |  United States  | 1985-1999 | 1421 | 5.5 ± 3.7 | 50 ± 12 | 55% | - | 8.8% (125) | - | - |
|  Saigal *et al*[[4](#_ENREF_28)] | 2003 |  United Kingdom  | 1988-1999 | 1140 | - | 51.5 | 70% | 3.8 ± 2.8 | 2.6% (30) | - | - |
|  Benlloch *et al*[[36](#_ENREF_28)] | 2004 |  Spain  | 1991-2001 | 772 | 4.3 | 50 | 59% | 3.5 | \*5.3% (41) | - | - |
|  Oo *et al*[[45](#_ENREF_28)] | 2005 |  United Kingdom  | 1982-2004 | 1778 | 6.5 | - | 43% | - | 7.9% (141) | - | SIR= 2.1 (95%CI= 1.7–2.2) |
|  Herrero *et al*[[7](#_ENREF_28)] | 2005 |  Spain  | 1990-2001 | 187 | 5.5 | - | - | - | 26% (49) | 25%/ 39%/ -/ - | RR= 2.9 (95%CI= 1.6-5.0) |
|  Yao *et al*[[40](#_ENREF_28)] | 2006 |  United States  | 1988-2000 | 1043 | 6.7 | 53.2 | 52% | - | 4.8% (50) | - | - |
|  Aberg *et al*[[9](#_ENREF_28)] | 2008 |  Finland  | 1982-2005 | 540 | 6.3 | - | 53% | 5.1 | ¥6.7% (36) | 5%/13%/ -/16% | 3SIR = 2.6(95%CI= 1.8-3.5] |
|  Jiang *et al*[[10](#_ENREF_28)] | 2008 |  Canada  | 1983-1998 | 2034 | - | - | 53% | 3.5 ± 2.8 | 5.5% (113) **1** | 2%/ 8.6%/ -/ - | SIR = 2.5**1** (95%CI: 2.1-3.0) |
|  Watt *et al*[[12](#_ENREF_28)] | 2009 |  United States  | 1990-1994 | 798 | 10 | - | 60%**1** | - | 21.4% (171) | 12%/ 22%/ -/ - | - |
|  Finkenstedt *et al*[[18](#_ENREF_28)] | 2009 |  Austria  | 1982-2007 | 779 | 4.1 | - | - | 4.4 | 12.3% (96) | 10%/24%/ 32%/42% | SIR = 1.9**1** (95%CI= 1.5-2.4) |
|  Baccarani *et al*[[17](#_ENREF_28)] | 2010 |  Italy  | 1991-2005 | 417 | 6.7 | - | 74% | 4.2 | DOI: 10.3% (43) **1** | - | SIR = 2.6**1** (95%CI= 1.9-3.6) |
| Tjon *et al*[[27](#_ENREF_28)] | 2010 | Denmark | 198-2007 | 85 | 5  | - | - | - | 3% (50) | 10%/19%/34%/- | SIR = 2.2 (95%CI: 6-.8) |
|  Park *et al*[[67](#_ENREF_28)] | 2012 |  Korea  | 1998-2008 | 1952 | 3.5 ± 2.8 | 56 | 79% | 3.4 ± 2.4 | **\***2.3% (44) | - | RR = 7.7**1** for men and 7.3 for women |
|  Chatrath *et al*[[2](#_ENREF_28)] | 2013 |  United States  | 1997-2004 | 534 | 5.7 ± 3.2 | 53±12 | 67% | 4 ± 2.2 | 13.7% (73) | 12%/ 25%/ -/ - | SIR = 3.1**1** (95%CI: 2.9-3.2) |
| Wimmer *et al*[[24](#_ENREF_28)] | 2013 | Germany | 1985-2007 | 609 | 5.2 | 53±10 | 73% | 5.7 | 11.5% (70) | 10%/26%/ 35%/- | - |
|  Ettorre *et al*[[11](#_ENREF_28)] | 2014 |  Italy  | 1990-2008 | 1675 | 5.2  | - | - | 3.2 | 5.9% (98) **1** | - | SIR = 1.4**1** (95%CI = 1.2-1.7) |
|  Yu *et al*[[69](#_ENREF_28)] | 2014 |  China  | 2005-2011 | 569 | 3.5 ± 2.2 | - | 76% | - | 3.2% (17) | - | - |
|  Antinucci *et al*[[117](#_ENREF_28)] | 2015 |  Argentina  | 2006-2014 | 168 | - | 67±7 | 75% | 1.3 | 7.5% (12) | - | - |
|  Sanei *et al*[[68](#_ENREF_28)] | 2015 |  Iran  | 1992-2012 | 1700 | - | 34±10 | 63% | 5.5 | 2.2% (38) | - | - |
| Overall means |  |  |  | 940 | 5.5 | 52 | 61% | 3.8 | 8.1% | 11%/22%/39%/29% | 3.0 |

1Excluding non-melanoma skin cancers; 2Excluding post-transplant lymphoproliferative disorder; 3Excluding basal cell skin cancer; 4Median or mean ± SD.

**Table 2 A listing on known oncogenic viruses and the malignancies associated with them**

|  |  |
| --- | --- |
| **Oncogenic virus** | **Associated malignancy** |
| Epstein Barr virus | PTLD |
| Human Papilloma Virus | Cervical, skin, oropharynx, anal |
| Human T-cell lymphotropic virus type 1 | Adult T cell leukemia |
| Kaposi's sarcoma-associated herpesvirus | KS, Primary effusion lymphoma, Castleman's disease  |
| Hepatitis B virus | HCC |
| Hepatitis C virus | HCC, PTLD1 |

1Role controversial. HCC: Hepatocellular carcinoma; PTLD: Post transplant lymphoproliferative disorder; KS: Kaposi's sarcoma.

**Table 3 A summary of ranges of reported overall incidence rates and standardized incidence ratios of a number of cancer types following liver transplantation[**[**2-5**](#_ENREF_2)**,**[**7-12**](#_ENREF_7)**,**[**14-16**](#_ENREF_14)**,**[**28**](#_ENREF_28)**,**[**36**](#_ENREF_36)**,**[**47**](#_ENREF_47)**,**[**66**](#_ENREF_66)**,**[**110**](#_ENREF_110)**,**[**118-120**](#_ENREF_118)**]**

|  |  |  |
| --- | --- | --- |
|  | **Incidence (%)** | **SIR (per 100000 patient years)** |
| ***Skin cancers*** Represent 24% - 54% of all cancers, average 37% |
| Overall (non-melanoma) | 0.9 - 11.6 | 2.1- 70,average 24 |
| Squamous cell cancer | 0.6 - 15.3 | Not reported |
| Basal cell cancer | 0.6 - DOI: 10.6 | Not reported |
| Kaposi's sarcoma | 0.2 - 1.4 | 128 - 144 |
| Melanoma | 0. 2 - 3.9 | 4.4 |
| *Post-transplant lymphoproliferative disorders*Represent 4% - 57% of all cancers, average 25% |
| Overall | 0.5 - 2.9 | 3.9 - 21,average 12 |
| Hodgkin's lymphoma | 0.001 - 0.4  | 8.2 - 8.9 |
| Non-Hodgkin's lymphoma | 0.8 - 3.7 | 3.5 - 37.3 |
| *Solid organ cancers* Represent 24% - 75% of all cancers, average 48% |
| Overall | 1.4 - 7.5 | 1.4 - 3.1,Average 2.3 |
| Lip  | 1.8 | 14 - 24.8 |
| Oropharyngeal | 1.7 - 1.9 | 7 - 10 |
| Lung | 0.6 - 2.4 | 1.4 - 2.0 |
| Stomach | 0.2 - 0.7 | 0.5 - 3.7 |
| Colorectal | 0.5 - 1.1 | 1.4 - 4.9 |
| Breast (in females) | 0.2- 0.6 | 0.6 - 1.61 |
| Cervix (in females) | 0.7 - 1.4 | 1.3 - 5.7 |
| Prostate (in males) | 0.2 - 1.8 | 0.6 - 1.61 |

1The SIR was not found to be significantly higher for transplant recipients compared with the reference population. Of note, studies often reported either incidence rate or SIR, but rarely both values. SIR: Standardized incidence ratio.